Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of Ifupinostat Hydrochloride for Injection (BEBT-908) Monotherapy in Relapsed/Refractory or Measurable Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia With MEF2D Rearrangement

NCT07854652 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT07854652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07854652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of Ifupinostat Hydrochloride for Injection (BEBT-908) Monotherapy in Relapsed/Refractory or Measurable Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia With MEF2D Rearrangement
Lead sponsor
The First Affiliated Hospital of Soochow University
Phase
Phase 1
Overall status
Recruiting
Start date
September 1, 2026
Completion date
August 30, 2030
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell precursor acute lymphoblastic leukemia (all)